ERBB2 and breast cancer: Considering the breast carcinoma subtypes in the UK the most commonly prescribed neoadjuvant chemotherapy regimes in breast cancers are: AC-containing combinations of fluorouracil, epirubicin and cyclophosphamide (FEC) with docetaxel/trastuzumab/pertuzumab for HER2-positive disease and FEC-docetaxel for HER2-negative disease (2).